Unió Europea - anglès - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate - hiv infections - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - treatment of human immunodeficiency virus 1 (hiv 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with hiv 1 without known mutations associated with resistance to any of the three antiretroviral agents in stribild.

Israel - anglès - Ministry of Health

gilead sciences israel ltd - sacituzumab govitecan - powder for concentrate for solution for infusion - sacituzumab govitecan 200 mg - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.trodelvy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Tanzània - anglès - Tanzania Medicinces & Medical Devices Authority

gilead sciences, inc, usa - emtricitabine , tenofovir disoproxil fumarate - tablets - 200

Aràbia Saudita - anglès - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gilead sciences ireland uc, ireland - emtricitabine,bictegravir,tenofovir alafenamide - film-coated tablet - 200,52.45,25 mg,

Aràbia Saudita - anglès - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gilead sciences ireland uc, ireland - remdesivir - powder for concentrate for solution for infusion - 100 mg

Unió Europea - anglès - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - hiv infections - antivirals for systemic use - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1).sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1).

Unió Europea - anglès - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infections - antivirals for systemic use - vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (hiv-1) infection in adults who are infected with hiv-1 without known mutations associated with resistance to elvitegravir.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil - tablet - 245mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - emtricitabine - capsule - 200mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - adefovir dipivoxil - tablet - 10mg